CR20110573A - Combinacion antitumoral que comprende ave8062 y sorafenib - Google Patents

Combinacion antitumoral que comprende ave8062 y sorafenib

Info

Publication number
CR20110573A
CR20110573A CR20110573A CR20110573A CR20110573A CR 20110573 A CR20110573 A CR 20110573A CR 20110573 A CR20110573 A CR 20110573A CR 20110573 A CR20110573 A CR 20110573A CR 20110573 A CR20110573 A CR 20110573A
Authority
CR
Costa Rica
Prior art keywords
ave8062
sorafenib
combination including
antitumoral combination
antitumoral
Prior art date
Application number
CR20110573A
Other languages
English (en)
Inventor
Brigitte Demers
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CR20110573A publication Critical patent/CR20110573A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una combinación antitumoral que asocia AVE8062 y sorafenib eficaz en el tratamiento de cánceres, mas particularmente de tumores sólidos.
CR20110573A 2009-05-07 2011-11-03 Combinacion antitumoral que comprende ave8062 y sorafenib CR20110573A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0902210A FR2945210B1 (fr) 2009-05-07 2009-05-07 Combinaison antitumorale comprenant l'ave8062 et le sorafenib

Publications (1)

Publication Number Publication Date
CR20110573A true CR20110573A (es) 2011-12-08

Family

ID=41402172

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20110573A CR20110573A (es) 2009-05-07 2011-11-03 Combinacion antitumoral que comprende ave8062 y sorafenib

Country Status (27)

Country Link
US (1) US20120108641A1 (es)
EP (1) EP2427185A1 (es)
JP (1) JP2012526090A (es)
KR (1) KR20120023754A (es)
CN (1) CN102438608A (es)
AR (1) AR076848A1 (es)
AU (1) AU2010244254A1 (es)
BR (1) BRPI1014197A2 (es)
CA (1) CA2761146A1 (es)
CL (1) CL2011002782A1 (es)
CO (1) CO6390102A2 (es)
CR (1) CR20110573A (es)
DO (1) DOP2011000335A (es)
EA (1) EA201171366A1 (es)
EC (1) ECSP11011440A (es)
FR (1) FR2945210B1 (es)
IL (1) IL216133A0 (es)
MA (1) MA33346B1 (es)
MX (1) MX2011011767A (es)
NI (1) NI201100191A (es)
PE (1) PE20120323A1 (es)
SG (1) SG175895A1 (es)
TN (1) TN2011000551A1 (es)
TW (1) TW201043225A (es)
UY (1) UY32618A (es)
WO (1) WO2010128259A1 (es)
ZA (1) ZA201108110B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2012014732A (es) * 2010-06-18 2013-01-22 Sanofi Sa Una combinacion antitumoral que comprende ombrabulina un derivado de taxano y un derivado de platino.
EP2481404A1 (en) * 2010-11-15 2012-08-01 Sanofi An antitumoral combination comprising ombrabulin, a taxane derivative and a platinum derivative
FR2968557A1 (fr) * 2010-12-09 2012-06-15 Sanofi Aventis Combinaison antitumorale comprenant un derive de la famille des combretastatines et le cetuximab
ES2627120T3 (es) 2011-07-08 2017-07-26 Helmholtz-Zentrum für Infektionsforschung GmbH Medicamento para el tratamiento del cáncer de hígado
FR2978662A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cisplatine, associee a la radiotherapie
FR2978663A1 (fr) 2011-08-01 2013-02-08 Sanofi Sa Combinaison antitumorale comprenant l'ombrabuline et le cetuximab, associee a la radiotherapie
WO2015126903A1 (en) * 2014-02-18 2015-08-27 Health Research, Inc. Combination therapy for hepatocellular carcinoma
KR102272993B1 (ko) * 2019-07-09 2021-07-06 충남대학교산학협력단 퀴니딘 유도체를 유효성분으로 함유하는 항암보조제

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW334418B (en) 1995-03-07 1998-06-21 Ajinomoto Kk Stilbene derivatives and pharmaceutical compositions
ATE328599T1 (de) * 1998-04-03 2006-06-15 Ajinomoto Kk Antitumorale mittel
ES2377847T3 (es) 1999-01-13 2012-04-02 Bayer Healthcare Llc Difenil ureas sustituidas con omega-carboxi arilo como agentes inhibidores de la cinasa p38
EP1140840B1 (en) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US20020183266A1 (en) * 2001-03-15 2002-12-05 Aventis Pharma, S.A. Combination comprising combretastatin and anticancer agents
CN101816794A (zh) * 2001-06-25 2010-09-01 味之素株式会社 抗肿瘤剂
EP1474393A1 (en) * 2002-02-11 2004-11-10 Bayer Pharmaceuticals Corporation Aryl ureas as kinase inhibitors
FR2838437B1 (fr) 2002-04-11 2004-06-04 Aventis Pharma Sa Procedes de preparation de combretastatines
FR2895258B1 (fr) * 2005-12-22 2008-03-21 Aventis Pharma Sa Combinaison comprenant de la combretastatine et des agents anticancereux
WO2008031835A2 (en) * 2006-09-13 2008-03-20 Novartis Ag Method of treating autoimmune diseases using vegf-pathway inhibitors

Also Published As

Publication number Publication date
FR2945210A1 (fr) 2010-11-12
CO6390102A2 (es) 2012-02-29
TN2011000551A1 (fr) 2013-05-24
EA201171366A1 (ru) 2012-05-30
BRPI1014197A2 (pt) 2016-04-26
CN102438608A (zh) 2012-05-02
WO2010128259A1 (fr) 2010-11-11
UY32618A (es) 2010-12-31
NI201100191A (es) 2012-01-16
MA33346B1 (fr) 2012-06-01
CA2761146A1 (fr) 2010-11-11
TW201043225A (en) 2010-12-16
FR2945210B1 (fr) 2011-07-01
DOP2011000335A (es) 2011-12-15
MX2011011767A (es) 2012-02-28
US20120108641A1 (en) 2012-05-03
ZA201108110B (en) 2013-01-30
AU2010244254A1 (en) 2011-11-24
CL2011002782A1 (es) 2012-03-30
KR20120023754A (ko) 2012-03-13
SG175895A1 (en) 2011-12-29
PE20120323A1 (es) 2012-04-17
IL216133A0 (en) 2012-01-31
AR076848A1 (es) 2011-07-13
ECSP11011440A (es) 2011-12-30
JP2012526090A (ja) 2012-10-25
EP2427185A1 (fr) 2012-03-14

Similar Documents

Publication Publication Date Title
CR20110573A (es) Combinacion antitumoral que comprende ave8062 y sorafenib
CY1123404T1 (el) Αντι-girt αντισωματα
CY1121663T1 (el) Μιγμα rp/sp gemcitαβινε- [ρηενyl-(benzyloxy-l-alανιnyl)]-phosphate
CY1119030T1 (el) Χρηση των δεσμων σιγμα στον πονο του καρκινου των οστων
MX2013006392A (es) Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1.
CR20120202A (es) Métodos y composiciones para tratar cáncer
CO6620019A2 (es) Métodos de tratamiento de cander de vejiga
EA201171367A1 (ru) Винилиндазолильные соединения
BR112013002012A2 (pt) métodos e composições para terapia de câncer de fígado
BR112014031421A2 (pt) composições para tratamento de câncer e métodos para produção das mesmas
UY4167Q (es) Par de auriculares
TR201813877T4 (tr) Spi̇nal müsküler atrofi̇ni̇n tedavi̇ edi̇lmesi̇ne yöneli̇k bi̇leşi̇kler.
EA201400178A1 (ru) Лечение рака молочной железы
CL2011003229A1 (es) Compuestos conjugados derivados de criptoficina; procedimiento de preparacion; y su uso para el tratamiento del cancer.
CR20110560A (es) Métodos de tratamiento para tumores sólidos
UY31432A1 (es) Compuestos de diarilhidantoina
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
IN2012DN02046A (es)
CR20110553A (es) Terapia complementaria contra el cáncer
MX349321B (es) Terapia combinada.
MX2012003851A (es) Tratamiento de cánceres resistentes antagonistas notch1, mediante el uso de antagonistas notch3.
MX358254B (es) Métodos para el tratamiento de cáncer de mama.
DK2252322T3 (da) Vaccinesammensætninger
CO6741197A2 (es) Proteína de fusión robo1-fc para uso en el tratamiento del hepatocarcinoma
UY33923A (es) Combinación antitumoral que comprende cabazitaxel y cisplatino